(Reuters) - The U.S. Food and Drug Administration said on Friday it approved a hormonal contraceptive device, providing American women another reversible contraceptive choice as effective as sterilization. Actavis Plc holds the commercial license to the device, the marketing application of which was submitted by non-profit pharmaceutical company Medicines360. Medicines360 holds the U.S. public sector clinic rights to the product. The t-shaped intrauterine device, Liletta, releases the hormone, levonorgestrel, to inhibit thickening of the womb lining, preventing pregnancy for up to three years. ... via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment